Capital Peptides
← All research overviews

5-Amino-1MQ (NNMT Inhibitor) Research Overview

Important Notice: All information provided is for educational and informational purposes only. All peptides mentioned are intended exclusively for laboratory and in-vitro research and are not approved to diagnose, treat, cure, or prevent any disease.

Simplified Summary

5-Amino-1MQ is a cell-permeable NNMT inhibitor studied in preclinical settings for its ability to reduce NNMT enzymatic activity and alter NAD+ metabolism. By inhibiting NNMT, the compound reduces nicotinamide catabolism, potentially elevating intracellular NAD+ pools and influencing sirtuin activity, epigenetic methyl donor availability, and adipocyte biology.

Key Findings Reported in Preclinical Models

  • Inhibition of adipocyte differentiation in preclinical cell culture systems, with reduced lipid accumulation and adipogenic gene expression markers in 3T3-L1 preadipocyte assays.
  • Elevation of cellular NAD+ levels in NNMT-inhibited in vitro and animal model systems, consistent with reduced nicotinamide catabolism.
  • Reduction in adipose tissue mass in preclinical diet-induced obesity rodent models.
  • Modulation of metabolic gene expression profiles in adipose tissue including genes related to lipogenesis, lipolysis, and mitochondrial biogenesis.
  • Sirtuin pathway activation indicators in preclinical metabolic assessments, with SIRT1 and SIRT3 activity markers elevated in response to increased NAD+ levels.

Introduction

NNMT catalyses the methylation of nicotinamide using S-adenosylmethionine (SAM) as the methyl donor, sitting at the intersection of NAD+ catabolism, one-carbon metabolism, and epigenetic regulation. Elevated NNMT expression has been identified in adipose tissue and liver under conditions of metabolic dysfunction, motivating investigation of NNMT inhibitors as metabolic research tools.

Research Applications

  • NNMT enzyme biology research using 5-Amino-1MQ to study consequences for NAD+ pools and SAM availability in adipocyte and hepatocyte model systems.
  • Adipogenesis and adipocyte differentiation research in in vitro preclinical models.
  • NAD+ metabolism and sirtuin pathway research in animal models.
  • Epigenetic metabolic regulation research investigating how NNMT inhibition influences DNA and histone methylation at metabolic gene loci.

For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.